title: Plasma lipid secretion and clearance in hyperlipidemic JCR:LA-corpulent rats.
abstract: The JCR:LA-corpulent rat is an obese, hyperlipidemic, hyperinsulinemic strain that is atherosclerosis-prone and develops myocardial lesions. The hyperlipidemia is due to elevated plasma levels of a large relatively triglyceride-rich very low density lipoprotein (VLDL). Both corpulent and lean male and female rats were studied. Postheparin lipid clearance and apparent hepatic secretion rate after Triton WR1339 inhibition of lipoprotein lipase were determined. The concentrations of cholesterol and cholesteryl esters were not significantly altered by either treatment. Triglycerides showed rapid postheparin clearance in corpulent rats. The apparent hepatic secretion rate was markedly higher in corpulent male rats than in lean male rats, and the rate in corpulent females was again higher, reflecting the higher serum triglyceride concentrations in corpulent female rats. The relative secretion rate of C:48 triglyceride molecular species was lower than that of the C:50 to C:56 species, while the postheparin clearance of C:48 triglyceride molecular species was impaired compared to the C:50 species and those with higher carbon numbers. This effect was more marked in the male than in the female corpulent rats. The results indicate that VLDL hyperlipidemia in the corpulent rat is due to hepatic hypersecretion of VLDL and not to a defect in lipoprotein lipase. Further, the atherogenesis that is characteristic of the corpulent male rat may be related to the differential metabolism of fatty acids.
authors.affiliation: Department of Surgery, University of Alberta, Edmonton, Canada.
authors.forename: J C
authors.initials: JC
authors.lastname: Russell
authors.forename: D G
authors.initials: DG
authors.lastname: Koeslag
authors.forename: R M
authors.initials: RM
authors.lastname: Amy
authors.forename: P J
authors.initials: PJ
authors.lastname: Dolphin
mesh_terms: D000818:Animals; D001810:Blood Volume; D001835:Body Weight; D005260:Female; D006493:Heparin / Q000494:pharmacology; D006949:Hyperlipidemias / Q000378:metabolism*; D008055:Lipids / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate; D009765:Obesity / Q000378:metabolism*; D010743:Phospholipids / Q000378:metabolism; D011092:Polyethylene Glycols / Q000494:pharmacology; D051381:Rats; D011922:Rats, Mutant Strains / Q000378:metabolism*; D014280:Triglycerides / Q000378:metabolism
chemical_list: D008055:Lipids; D008079:Lipoproteins, VLDL; D010743:Phospholipids; D014280:Triglycerides; D011092:Polyethylene Glycols; D006493:Heparin; C016811:tyloxapol